A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Condition: Metastatic Breast Cancer
MeSH terms: Breast Neoplasms
Intervention: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg; Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg; Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Intervention description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.; Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.; Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Intervention MeSH terms: Paclitaxel; Epothilones; Bevacizumab
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 136.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is
      effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy
      in participants with metastatic breast cancer. The study will also assess the safety of this
      combination treatment.
    

Eligibility criteria:

        Inclusion criteria:

          -  Locally recurrent or metastatic breast cancer, previously untreated with chemotherapy
             for advanced disease.

          -  At least 1 target lesion per RECIST criteria. Locally recurrent disease must not be
             amenable to resection with curative intent.

          -  No previous cytotoxic chemotherapy for locally recurrent/metastatic disease.

          -  Relapse 12 months or more after completing prior adjuvant or neoadjuvant taxane
             therapy.

          -  No previous breast cancer known to overexpress or amplify the human epidermal growth
             factor receptor 2 gene.

          -  Prior hormonal therapy in adjuvant, recurrent, or metastatic setting allowed but must
             have been discontinued at least 2 weeks before randomization.

          -  Karnofsky performance status of 80 to 100 or Eastern Cooperative Oncology Group
             performance status of 0 to 1.

          -  Estimated life expectancy of at least 12 weeks.

          -  Recovery from recent therapy (except for alopecia), including chemotherapy,
             immunotherapy, biologic therapy, or investigational product. Any such therapy must
             have been completed at least 3 weeks before randomization and at least 6 weeks from
             use of nitrosourea, or mitomycin.

          -  Recovery from recent surgery and radiation therapy. At least 1 week since minor
             surgery and/or focal/palliative radiation therapy; at least 3 weeks from radiation; at
             least 4 weeks from major surgery; and at least 8 weeks from liver resection,
             thoracotomy, or neurosurgery.

          -  Absolute neutrophil count ≥1500/mm^3.

          -  Hemoglobin ≥9 g/dL.

          -  Platelets ≥100,000/mm^3.

          -  Total bilirubin ≤1.5 times the upper limit of normal (ULN).

          -  Aspartate aminotransferase or alanine aminotransferase ≤2.5*ULN.

          -  Normal partial thromboplastin time and either international normalized ratio or
             prothrombin time <1.5*ULN.

          -  Serum creatinine ≤1.5*ULN or 24-hour creatinine clearance >60 mL/min.

          -  Urine dipstick for proteinuria <2+ (negative, trace, or +1). Participants with ≥2+
             proteinuria at baseline were to undergo 24-hour urine collection and demonstrate ≤1g
             of protein in 24 hours to be eligible.

        Exclusion criteria:

          -  Women of child-bearing potential (WOCBP) unwilling or unable to use an acceptable
             method of birth control to avoid pregnancy for the entire study period and up to 6
             months after treatment with bevacizumab.

          -  Women who were pregnant or breastfeeding.

          -  Women with a positive pregnancy test on enrollment or prior to study drug
             administration.

          -  Sexually active fertile men, whose partners were WOCBP, not using an adequate method
             of birth control.

          -  Evidence of baseline sensory or motor neuropathy.

          -  Serious infection or nonmalignant medical illnesses uncontrolled or the control of
             which could be jeopardized by this therapy.

          -  History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess,
             serious gastric ulcer, or bone fracture within 6 months of study entry.

          -  History of hypertensive crisis or hypertensive encephalopathy.

          -  Significant vascular disease.

          -  Clinically significant cardiovascular disease.

          -  Baseline left ventricular ejection fraction by multiple-gated acquisition scan or
             echocardiogram for subjects with prior exposure to anthracyclines not within
             institutional normal limits.

          -  Symptomatic peripheral vascular disease.

          -  History of high dose chemotherapy with bone marrow transplant or peripheral blood stem
             cell transplant within the previous 2 years.

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Prior treatment with an epothilone or any antiangiogenic agent.

          -  Concurrent nonhealing wound, ulcer, or fracture.

          -  Any current or history of brain and/or leptomeningeal metastases. Psychiatric
             disorders or other conditions rendering the participant incapable of complying with
             the requirements of the protocol.

          -  Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in
             situ of the cervix.

          -  Known allergy to any of the study drugs or their excipients.